|Articles|May 1, 2002

Second course of efalizumab improves response in psoriatics

New Orleans-Psoriatic patients who responded partially or not at all to initial treatment with efalizumab (Xanelim) responded more positively and without significant adverse events during a second course of treatment.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME